Conclusions
This randomized clinical trial found that the addition of disulfiram and copper to alkylating chemotherapy did not improve survival in patients with recurrent GB. Instead, the treatment regimen of 400 mg disulfiram daily resulted in significantly more toxic effects. These results suggest that disulfiram and copper is not of benefit in patients with recurrent GB.